NCT01261247 - Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 17, 2011

Primary Completion Date

May 9, 2016

Study Completion Date

December 2, 2019

Conditions

Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueHepatosplenic T-cell LymphomaNodal Marginal Zone B-cell LymphomaPeripheral T-cell LymphomaPost-transplant Lymphoproliferative DisorderRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent Small Lymphocytic LymphomaSmall Intestine LymphomaSplenic Marginal Zone LymphomaWaldenstrom Macroglobulinemia

Interventions

DRUG

panobinostat

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

GENETIC

western blotting

Correlative studies

GENETIC

DNA analysis

Correlative studies

OTHER

flow cytometry

Correlative studies

OTHER

pharmacological study

Correlative studies

OTHER

immunohistochemistry staining method

Optional correlative studies

Trial Locations (2)

55905

Mayo Clinic, Rochester

Unknown

Mayo Clinic in Arizona, Scottsdale